title: Challenges and recent advancements in infectious laryngotracheitis virus vaccines.
abstract: Over the past 80 years, biosecurity measures and vaccines have been used to prevent the occurrence of outbreaks of infectious laryngotracheitis (ILT). Despite these control strategies, ILT continues to have an impact on intensive poultry industries. Attenuated vaccines, particularly those derived by passage in chicken embryos, have been associated with a number of side effects, including residual virulence, transmission to naïve birds, establishment of latent infections with subsequent reactivation and shedding of virus, and reversion to virulence after in vivo passage. Most recently, recombination between attenuated ILT vaccines in the field has been shown to be responsible for the emergence of new virulent viruses that have caused widespread disease. To address some of these issues, new-generation virally vectored recombinant vaccines have been developed and recently released in some countries. In addition, recombinant deletion mutants of ILT virus have been proposed as vaccine candidates. In this review, recent advances in the understanding of the epidemiology of traditionally attenuated ILT vaccines as well as in the development and use of new generation vaccines are examined. Next-generation vaccines, along with more appropriate immunological screening strategies, are identified as particularly promising options to enhance ILT control in the future.
authors.affiliation: Asia-Pacific Centre for Animal Health, Faculty of Veterinary Science, The University of Melbourne, Corner Park Drive and Flemington Road, Victoria 3010, Australia. mjcoppo@unimelb.edu.au
authors.forename: Mauricio J C
authors.initials: MJ
authors.lastname: Coppo
authors.forename: Amir H
authors.initials: AH
authors.lastname: Noormohammadi
authors.forename: Glenn F
authors.initials: GF
authors.lastname: Browning
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Devlin
mesh_terms: D000818:Animals; D001315:Australia / Q000453:epidemiology; D004333:Drug Administration Routes / Q000662:veterinary; D006566:Herpesviridae Infections / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D001352:Herpesvirus 1, Gallid / Q000276:immunology*; D011200:Poultry; D011201:Poultry Diseases / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology*; D013020:South America / Q000453:epidemiology; D014481:United States / Q000453:epidemiology; D014614:Vaccines, Synthetic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D014614:Vaccines, Synthetic; D014765:Viral Vaccines